Launching ILUVIEN

This start-up pharmaceutical company focuses on diseases of the retina and needed help bringing its flagship product to market in France, Germany and the United Kingdom. ILUVIEN is an exciting new way to treat patients with diabetic macular edema (DME) that provides sustained levels of fluocinolone acetonide from a single implant for 36 months.

  • Fingerpaint is Agency of the Year according to MedAdNews

An international success

Fingerpaint developed and executed a global advertising and marketing strategy within a complex regulatory environment, then worked with a network of global partners to market and drive sales of ILUVIEN. Within six months of launch, the company saw huge growth in corporate and product awareness—and enrolled a significant percentage of target retina specialists for training.